Innovative Research Award
| Kai-bo Wang | |
|---|---|
| Affiliation | China Pharmaceutical University |
| Country | China |
| Scopus ID | 56308249700 |
| Documents | 46 |
| Citations | 1299 |
| h-index | 23 |
| Subject Area | Dairy Science and Technology |
| Event | International Food Scientist Awards |
Kai-bo Wang
China Pharmaceutical University,China
Kai-bo Wang is a distinguished medicinal chemist and researcher at China Pharmaceutical University whose work focuses on DNA G-quadruplex biology, cancer therapeutics, and molecular pharmacology. His investigations into G-quadruplex structures and associated protein interactions have contributed to understanding novel therapeutic targets for cancer, infectious diseases, and age-related disorders.[1]
Contents
Abstract
Kaibo Wang is a leading researcher in medicinal chemistry whose work focuses on DNA G-quadruplex structures and their therapeutic applications. His research combines chemical biology, structural analysis, and molecular pharmacology to develop innovative strategies for targeting cancer-related genes and protein interactions. Through studies published in internationally recognized journals, he has advanced understanding of genome regulation, drug discovery, and targeted therapeutics, contributing valuable insights to cancer treatment and pharmaceutical research.[1]
Keywords
DNA G-Quadruplexes, Cancer Therapeutics, Medicinal Chemistry, Molecular Pharmacology, Genome Stability, Drug Discovery.
Introduction
After earning his doctorate from Shenyang Pharmaceutical University and completing postdoctoral training at Purdue University, Professor Wang established an internationally visible research program focused on G-quadruplex-targeted therapeutics and structural biology.[1]
Research Profile
His laboratory employs biochemical assays, NMR spectroscopy, X-ray crystallography, cryo-electron microscopy, and cellular studies to characterize oncogenic G-quadruplexes and identify drug candidates targeting critical disease pathways.
Research Contributions
Major contributions include the characterization of MYC, KRAS, EGFR, MET, ATF4, BLM, and NEIL3 promoter G-quadruplexes and the discovery of novel G4-interacting proteins such as nucleolin, LRPPRC, and STAT1.[3]
Publications
- Journal of the American Chemical Society
- Nature Communications
- Angewandte Chemie International Edition
- Nucleic Acids Research
- Organic Letters
Research Impact
His publications have advanced the understanding of nucleic acid structures and their relevance to drug discovery. The translational nature of his research has strengthened opportunities for innovative therapeutic development.
Award Suitability
Professor Wang’s sustained publication record, leadership of funded projects, and impactful discoveries in medicinal chemistry support recognition within international research excellence and innovation award categories.
Conclusion
Through pioneering studies of DNA G-quadruplexes and therapeutic targeting strategies, Professor Kaibo Wang continues to contribute significantly to medicinal chemistry, cancer biology, and molecular medicine.
External Links
References
-
- Li Y. et al. Nature Communications (2026).
https://doi.org/10.1038/s41467-026-73806-6 - Liu Y. et al. JACS (2023).
- Wang, Y., Zhang, X., Bian, Y., et al. (2026). A small molecule disrupts G4-STAT1 interaction and synergizes with olaparib to drive cancer cell death. Nucleic Acids Research. https://academic.oup.com/nar
- Zhang, L., Han, K., Wang, X., et al. (2026). Structure-informed design of distinct parallel promoter G-quadruplex stabilizers for KRAS-driven cancer therapy. Angewandte Chemie International Edition.
https://onlinelibrary.wiley.com/journal/15213773
- Li Y. et al. Nature Communications (2026).